Avidity Biosciences(RNA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in people living with DMD44 in Phase 1/2 EXPLORE44™ trial Initiated global Phase 3 HARBOR™ trial and began administration of del-desiran in people living with DM1; del-desiran received FDA Breakthrough Therapy designation Avidity plans to accelerate init ...